1015TiP Ramucirumab in patients with advanced hepatocellular carcinoma and elevated alpha fetoprotein following a non-sorafenib based systemic therapy: An expansion cohort of the phase III REACH-2 study
Richard S. Finn(University of California, Los Angeles), S. Qin, Peter R. Galle(Johannes Gutenberg University Mainz), C. Wang(Eli Lilly (United States)), Kenyon D. Ogburn(Eli Lilly (United States)), Ryan C. Widau(Eli Lilly (United States)), Andrew X. Zhu(Harvard University)
Cited by 3
Abstract
Related Papers
No related papers found
Powered by citation graph analysis